Rituxan Sales Hurt By Medicare Part B Changes; Demand “Still Strong,” Genentech Says
Sales for the oncologic stabilized during the second half of the quarter, however Genentech is not prepared to say “everything is going to be normal going forward.”
Sales for the oncologic stabilized during the second half of the quarter, however Genentech is not prepared to say “everything is going to be normal going forward.”